PointState Capital’s Pfizer PFE Stock Holding History

PointState Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,300,000	Closed	-$195M	–	114
2021 Q4	$195M	Buy	+3,300,000	New	+$164M	3.23%	10

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PointState Capital's PFE Position: Q3 2022 in Review

PointState Capital sold out of Pfizer (PFE) in Q3 2022, closing a stake of 123,005 shares — an estimated $6.45M sold.

PointState Capital first reported a position in PFE in Q3 2020 and held it in 4 quarters. The position peaked at $23M in Q3 2020. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.

PointState Capital reported no remaining Pfizer position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 123,005 Pfizer shares in Q3 2022, an estimated $6.45M.
PointState Capital first reported a position in Pfizer in Q3 2020 and held it in 4 quarters.
PointState Capital's Pfizer position peaked at $23M in Q3 2020.
3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.